| Ticker | Action | Number of Shares Bought/Sold | Value of Shares Added/Sold | Average Price paid for previous share BUYs |
|---|
| 2413.T - M3, Inc. | HOLD | 0 @ JPY 13.2617 | JPY 0 | The current share valuation price of 2413.T based on adjusted close was JPY 13.2617. The average price that 2413.T shares were previous bought at was JPY 14.3429. The current market price is -7.5% lower than average price they were purchased at. The value of the holding in 2413.T has increased by JPY 2,797 (USD $18) compared to the previous valuation of M3, Inc. however if the holding was sold on 2025-12-23 this would crystalise an overall loss. |
| 4151.T - Kyowa Kirin Co., Ltd. | HOLD | 0 @ JPY 16.1679 | JPY 0 | The current share valuation price of 4151.T based on adjusted close was JPY 16.1679. The average price that 4151.T shares were previous bought at was JPY 15.8711. The current market price is 1.9% higher than average price they were purchased at. The value of the holding in 4151.T has increased by JPY 9,936 (USD $63) compared to the previous valuation of Kyowa Kirin Co., Ltd. however if the holding was sold on 2025-12-23 this would crystalise an overall loss. |
| 4502.T - Takeda Pharmaceutical Company Limited | HOLD | 0 @ JPY 30.8396 | JPY 0 | The current share valuation price of 4502.T based on adjusted close was JPY 30.8396. The average price that 4502.T shares were previous bought at was JPY 28.8091. The current market price is 7.0% higher than average price they were purchased at. The value of the holding in 4502.T has increased by JPY 36,415 (USD $232) compared to the previous valuation of Takeda Pharmaceutical Company Limited however if the holding was sold on 2025-12-23 this would crystalise an overall loss. |
| 4503.T - Astellas Pharma Inc. | HOLD | 0 @ JPY 13.4695 | JPY 0 | The current share valuation price of 4503.T based on adjusted close was JPY 13.4695. The average price that 4503.T shares were previous bought at was JPY 11.3723. The current market price is 18.4% higher than average price they were purchased at. The value of the holding in 4503.T has increased by JPY 105,340 (USD $671) compared to the previous valuation of Astellas Pharma Inc. however if the holding was sold on 2025-12-23 this would crystalise an overall loss. |
| 4507.T - Shionogi & Co., Ltd. | HOLD | 0 @ JPY 17.8304 | JPY 0 | The current share valuation price of 4507.T based on adjusted close was JPY 17.8304. The average price that 4507.T shares were previous bought at was JPY 17.0829. The current market price is 4.4% higher than average price they were purchased at. The value of the holding in 4507.T has increased by JPY 9,993 (USD $64) compared to the previous valuation of Shionogi & Co., Ltd. however if the holding was sold on 2025-12-23 this would crystalise an overall loss. |
| 4519.T - Chugai Pharmaceutical Co., Ltd. | HOLD | 0 @ JPY 53.3282 | JPY 0 | The current share valuation price of 4519.T based on adjusted close was JPY 53.3282. The average price that 4519.T shares were previous bought at was JPY 48.0143. The current market price is 11.1% higher than average price they were purchased at. The value of the holding in 4519.T has increased by JPY 59,963 (USD $382) compared to the previous valuation of Chugai Pharmaceutical Co., Ltd. however if the holding was sold on 2025-12-23 this would crystalise an overall loss. |
| 4523.T - Eisai Co., Ltd. | HOLD | 0 @ JPY 29.1259 | JPY 0 | The current share valuation price of 4523.T based on adjusted close was JPY 29.1259. The average price that 4523.T shares were previous bought at was JPY 30.3773. The current market price is -4.1% lower than average price they were purchased at. The value of the holding in 4523.T has increased by JPY 42,302 (USD $270) compared to the previous valuation of Eisai Co., Ltd. however if the holding was sold on 2025-12-23 this would crystalise an overall loss. |
| 4543.T - Terumo Corporation | HOLD | 0 @ JPY 14.8059 | JPY 0 | The current share valuation price of 4543.T based on adjusted close was JPY 14.8059. The average price that 4543.T shares were previous bought at was JPY 16.2004. The current market price is -8.6% lower than average price they were purchased at. The value of the holding in 4543.T has increased by JPY 5,295 (USD $34) compared to the previous valuation of Terumo Corporation however if the holding was sold on 2025-12-23 this would crystalise an overall loss. |
| 4568.T - Daiichi Sankyo Company, Limited | HOLD | 0 @ JPY 21.3057 | JPY 0 | The current share valuation price of 4568.T based on adjusted close was JPY 21.3057. The average price that 4568.T shares were previous bought at was JPY 26.9689. The current market price is -21.0% lower than average price they were purchased at. The value of the holding in 4568.T has increased by JPY 95,346 (USD $608) compared to the previous valuation of Daiichi Sankyo Company, Limited however if the holding was sold on 2025-12-23 this would crystalise an overall loss. |
| 4578.T - Otsuka Holdings Co., Ltd. | HOLD | 0 @ JPY 58.7058 | JPY 0 | The current share valuation price of 4578.T based on adjusted close was JPY 58.7058. The average price that 4578.T shares were previous bought at was JPY 55.9959. The current market price is 4.8% higher than average price they were purchased at. The value of the holding in 4578.T has increased by JPY 8,325 (USD $53) compared to the previous valuation of Otsuka Holdings Co., Ltd. however if the holding was sold on 2025-12-23 this would crystalise an overall loss. |
| 6869.T - Sysmex Corporation | HOLD | 0 @ JPY 10.0934 | JPY 0 | The current share valuation price of 6869.T based on adjusted close was JPY 10.0934. The average price that 6869.T shares were previous bought at was JPY 11.5634. The current market price is -12.7% lower than average price they were purchased at. The value of the holding in 6869.T has increased by JPY 43,113 (USD $275) compared to the previous valuation of Sysmex Corporation however if the holding was sold on 2025-12-23 this would crystalise an overall loss. |
| 7733.T - Olympus Corporation | HOLD | 0 @ JPY 12.7662 | JPY 0 | The current share valuation price of 7733.T based on adjusted close was JPY 12.7662. The average price that 7733.T shares were previous bought at was JPY 12.7889. The current market price is -0.2% lower than average price they were purchased at. The value of the holding in 7733.T has increased by JPY 1,781 (USD $11) compared to the previous valuation of Olympus Corporation however if the holding was sold on 2025-12-23 this would crystalise an overall loss. |
| 7741.T - HOYA Corporation | HOLD | 0 @ JPY 153.079 | JPY 0 | The current share valuation price of 7741.T based on adjusted close was JPY 153.079. The average price that 7741.T shares were previous bought at was JPY 143.245. The current market price is 6.9% higher than average price they were purchased at. The value of the holding in 7741.T has increased by JPY 4,514 (USD $29) compared to the previous valuation of HOYA Corporation however if the holding was sold on 2025-12-23 this would crystalise an overall loss. |
| A - Agilent Technologies Inc | HOLD | 0 @ USD 138.36 | USD 0 | The current share valuation price of A based on adjusted close was USD 138.36. The average price that A shares were previous bought at was USD 137.021. The current market price is 1.0% higher than average price they were purchased at. The value of the holding in A has fallen by USD 9,314 compared to the previous valuation of Agilent Technologies Inc |
| ABBV - AbbVie Inc | HOLD | 0 @ USD 228.79 | USD 0 | The current share valuation price of ABBV based on adjusted close was USD 228.79. The average price that ABBV shares were previous bought at was USD 208.919. The current market price is 9.5% higher than average price they were purchased at. The value of the holding in ABBV has increased by USD 135,463 compared to the previous valuation of AbbVie Inc however if the holding was sold on 2025-12-23 this would crystalise an overall loss. |
| ABT - Abbott Laboratories | HOLD | 0 @ USD 124.54 | USD 0 | The current share valuation price of ABT based on adjusted close was USD 124.54. The average price that ABT shares were previous bought at was USD 131.291. The current market price is -5.1% lower than average price they were purchased at. The value of the holding in ABT has fallen by USD 61,052 compared to the previous valuation of Abbott Laboratories |
| ALC.SW - | HOLD | 0 @ CHF 80.2684 | CHF 0 | The current share valuation price of ALC.SW based on adjusted close was CHF 80.2684. The average price that ALC.SW shares were previous bought at was CHF 78.0808. The current market price is 2.8% higher than average price they were purchased at. The value of the holding in ALC.SW has fallen by CHF 39,206 (USD $49,538) compared to the previous valuation of |
| ALNY - Alnylam Pharmaceuticals Inc | HOLD | 0 @ USD 398.7 | USD 0 | The current share valuation price of ALNY based on adjusted close was USD 398.7. The average price that ALNY shares were previous bought at was USD 419.862. The current market price is -5.0% lower than average price they were purchased at. The value of the holding in ALNY has fallen by USD 100,549 compared to the previous valuation of Alnylam Pharmaceuticals Inc |
| AMGN - Amgen Inc | HOLD | 0 @ USD 331.49 | USD 0 | The current share valuation price of AMGN based on adjusted close was USD 331.49. The average price that AMGN shares were previous bought at was USD 304.467. The current market price is 8.9% higher than average price they were purchased at. The value of the holding in AMGN has increased by USD 3,849 compared to the previous valuation of Amgen Inc however if the holding was sold on 2025-12-23 this would crystalise an overall loss. |
| ARGX.BR - Argenx SE | HOLD | 0 @ EUR 848.506 | EUR 0 | The current share valuation price of ARGX.BR based on adjusted close was EUR 848.506. The average price that ARGX.BR shares were previous bought at was EUR 850.325. The current market price is -0.2% lower than average price they were purchased at. The value of the holding in ARGX.BR has fallen by EUR 26,679 (USD $31,390) compared to the previous valuation of Argenx SE |
| AZN.L - AstraZeneca PLC | HOLD | 0 @ GBP 185.209 | GBP 0 | The current share valuation price of AZN.L based on adjusted close was GBP 185.209. The average price that AZN.L shares were previous bought at was GBP 135.46. The current market price is 36.7% higher than average price they were purchased at. The value of the holding in AZN.L has increased by GBP 273,388 (USD $368,251) compared to the previous valuation of AstraZeneca PLC however if the holding was sold on 2025-12-23 this would crystalise an overall loss. |
| BAX - Baxter International Inc | HOLD | 0 @ USD 18.93 | USD 0 | The current share valuation price of BAX based on adjusted close was USD 18.93. The average price that BAX shares were previous bought at was USD 19.3371. The current market price is -2.1% lower than average price they were purchased at. The value of the holding in BAX has fallen by USD 817 compared to the previous valuation of Baxter International Inc |
| BAYN.DE - Bayer AG | HOLD | 0 @ EUR 42.3194 | EUR 0 | The current share valuation price of BAYN.DE based on adjusted close was EUR 42.3194. The average price that BAYN.DE shares were previous bought at was EUR 33.7649. The current market price is 25.3% higher than average price they were purchased at. The value of the holding in BAYN.DE has increased by EUR 12,862 (USD $15,133) compared to the previous valuation of Bayer AG however if the holding was sold on 2025-12-23 this would crystalise an overall loss. |
| BDX - Becton Dickinson and Company | HOLD | 0 @ USD 195.67 | USD 0 | The current share valuation price of BDX based on adjusted close was USD 195.67. The average price that BDX shares were previous bought at was USD 186.211. The current market price is 5.1% higher than average price they were purchased at. The value of the holding in BDX has fallen by USD 6,702 compared to the previous valuation of Becton Dickinson and Company |
| BIIB - Biogen Inc | HOLD | 0 @ USD 174.82 | USD 0 | The current share valuation price of BIIB based on adjusted close was USD 174.82. The average price that BIIB shares were previous bought at was USD 174.262. The current market price is 0.3% higher than average price they were purchased at. The value of the holding in BIIB has increased by USD 1,147 compared to the previous valuation of Biogen Inc however if the holding was sold on 2025-12-23 this would crystalise an overall loss. |
| BIM.PA - BioMerieux | HOLD | 0 @ EUR 129.054 | EUR 0 | The current share valuation price of BIM.PA based on adjusted close was EUR 129.054. The average price that BIM.PA shares were previous bought at was EUR 126.635. The current market price is 1.9% higher than average price they were purchased at. The value of the holding in BIM.PA has fallen by EUR 3,409 (USD $4,011) compared to the previous valuation of BioMerieux |
| BMY - Bloomsbury Publishing Plc | HOLD | 0 @ USD 54.28 | USD 0 | The current share valuation price of BMY based on adjusted close was USD 54.28. The average price that BMY shares were previous bought at was USD 47.8261. The current market price is 13.5% higher than average price they were purchased at. The value of the holding in BMY has fallen by USD 50,087 compared to the previous valuation of Bloomsbury Publishing Plc |
| BSX - Boston Scientific Corporation | HOLD | 0 @ USD 96.09 | USD 0 | The current share valuation price of BSX based on adjusted close was USD 96.09. The average price that BSX shares were previous bought at was USD 99.7328. The current market price is -3.7% lower than average price they were purchased at. The value of the holding in BSX has fallen by USD 12,034 compared to the previous valuation of Boston Scientific Corporation |
| BSX - MULSTRXSSXIMETFP | HOLD | 0 @ USD 96.09 | USD 0 | The current share valuation price of BSX based on adjusted close was USD 96.09. The average price that BSX shares were previous bought at was USD 99.7328. The current market price is -3.7% lower than average price they were purchased at. The value of the holding in BSX has fallen by USD 12,034 compared to the previous valuation of MULSTRXSSXIMETFP |
| CAH - Cardinal Health Inc | HOLD | 0 @ USD 207.37 | USD 0 | The current share valuation price of CAH based on adjusted close was USD 207.37. The average price that CAH shares were previous bought at was USD 174.057. The current market price is 19.1% higher than average price they were purchased at. The value of the holding in CAH has increased by USD 112,043 compared to the previous valuation of Cardinal Health Inc however if the holding was sold on 2025-12-23 this would crystalise an overall loss. |
| CI - Cigna Corp | HOLD | 0 @ USD 273.75 | USD 0 | The current share valuation price of CI based on adjusted close was USD 273.75. The average price that CI shares were previous bought at was USD 287.321. The current market price is -4.7% lower than average price they were purchased at. The value of the holding in CI has fallen by USD 71,227 compared to the previous valuation of Cigna Corp |
| CNC - Concurrent Technologies Plc | HOLD | 0 @ USD 39.6 | USD 0 | The current share valuation price of CNC based on adjusted close was USD 39.6. The average price that CNC shares were previous bought at was USD 39.0871. The current market price is 1.3% higher than average price they were purchased at. The value of the holding in CNC has fallen by USD 34,422 compared to the previous valuation of Concurrent Technologies Plc |
| COH.AX - | HOLD | 0 @ AUD 175.665 | AUD 0 | The current share valuation price of COH.AX based on adjusted close was AUD 175.665. The average price that COH.AX shares were previous bought at was AUD 182.489. The current market price is -3.7% lower than average price they were purchased at. The value of the holding in COH.AX has increased by AUD 49,212 (USD $32,767) compared to the previous valuation of however if the holding was sold on 2025-12-23 this would crystalise an overall loss. |
| COLO-B.CO - | HOLD | 0 @ DKK 85.5686 | DKK 0 | The current share valuation price of COLO-B.CO based on adjusted close was DKK 85.5686. The average price that COLO-B.CO shares were previous bought at was DKK 90.9716. The current market price is -5.9% lower than average price they were purchased at. The value of the holding in COLO-B.CO has fallen by DKK 37,359 (USD $5,885) compared to the previous valuation of |
| COO - The Cooper Companies, Inc. Common Stock | HOLD | 0 @ USD 82.88 | USD 0 | The current share valuation price of COO based on adjusted close was USD 82.88. The average price that COO shares were previous bought at was USD 76.0608. The current market price is 9.0% higher than average price they were purchased at. The value of the holding in COO has fallen by USD 19,041 compared to the previous valuation of The Cooper Companies, Inc. Common Stock |
| COR - Cencora Inc. | HOLD | 0 @ USD 340.59 | USD 0 | The current share valuation price of COR based on adjusted close was USD 340.59. The average price that COR shares were previous bought at was USD 326.155. The current market price is 4.4% higher than average price they were purchased at. The value of the holding in COR has increased by USD 21,748 compared to the previous valuation of Cencora Inc. however if the holding was sold on 2025-12-23 this would crystalise an overall loss. |
| CSL.AX - | HOLD | 0 @ AUD 117.543 | AUD 0 | The current share valuation price of CSL.AX based on adjusted close was AUD 117.543. The average price that CSL.AX shares were previous bought at was AUD 119.767. The current market price is -1.9% lower than average price they were purchased at. The value of the holding in CSL.AX has increased by AUD 4,730 (USD $3,149) compared to the previous valuation of however if the holding was sold on 2025-12-23 this would crystalise an overall loss. |
| CVS - CVS Health Corp | HOLD | 0 @ USD 78.04 | USD 0 | The current share valuation price of CVS based on adjusted close was USD 78.04. The average price that CVS shares were previous bought at was USD 71.7416. The current market price is 8.8% higher than average price they were purchased at. The value of the holding in CVS has fallen by USD 25,418 compared to the previous valuation of CVS Health Corp |
| DEMANT.CO - | HOLD | 0 @ DKK 33.7356 | DKK 0 | The current share valuation price of DEMANT.CO based on adjusted close was DKK 33.7356. The average price that DEMANT.CO shares were previous bought at was DKK 34.9724. The current market price is -3.5% lower than average price they were purchased at. The value of the holding in DEMANT.CO has increased by DKK 12,344 (USD $1,944) compared to the previous valuation of however if the holding was sold on 2025-12-23 this would crystalise an overall loss. |
| DGX - Quest Diagnostics Incorporated | HOLD | 0 @ USD 175.08 | USD 0 | The current share valuation price of DGX based on adjusted close was USD 175.08. The average price that DGX shares were previous bought at was USD 181.702. The current market price is -3.6% lower than average price they were purchased at. The value of the holding in DGX has fallen by USD 3,034 compared to the previous valuation of Quest Diagnostics Incorporated |
| DHR - Danaher Corporation | HOLD | 0 @ USD 230.83 | USD 0 | The current share valuation price of DHR based on adjusted close was USD 230.83. The average price that DHR shares were previous bought at was USD 211.329. The current market price is 9.2% higher than average price they were purchased at. The value of the holding in DHR has increased by USD 138,738 compared to the previous valuation of Danaher Corporation however if the holding was sold on 2025-12-23 this would crystalise an overall loss. |
| DHR - Danaher Corporation | HOLD | 0 @ USD 230.83 | USD 0 | The current share valuation price of DHR based on adjusted close was USD 230.83. The average price that DHR shares were previous bought at was USD 211.329. The current market price is 9.2% higher than average price they were purchased at. The value of the holding in DHR has increased by USD 138,738 compared to the previous valuation of Danaher Corporation however if the holding was sold on 2025-12-23 this would crystalise an overall loss. |
| DIM.PA - Sartorius Stedim Biotech | HOLD | 0 @ EUR 243.154 | EUR 0 | The current share valuation price of DIM.PA based on adjusted close was EUR 243.154. The average price that DIM.PA shares were previous bought at was EUR 223.94. The current market price is 8.6% higher than average price they were purchased at. The value of the holding in DIM.PA has fallen by EUR 171 (USD $201) compared to the previous valuation of Sartorius Stedim Biotech |
| DXCM - DexCom Inc | HOLD | 0 @ USD 66.86 | USD 0 | The current share valuation price of DXCM based on adjusted close was USD 66.86. The average price that DXCM shares were previous bought at was USD 68.718. The current market price is -2.7% lower than average price they were purchased at. The value of the holding in DXCM has fallen by USD 7,023 compared to the previous valuation of DexCom Inc |
| EL.PA - EssilorLuxottica SA | HOLD | 0 @ EUR 318.043 | EUR 0 | The current share valuation price of EL.PA based on adjusted close was EUR 318.043. The average price that EL.PA shares were previous bought at was EUR 342.564. The current market price is -7.2% lower than average price they were purchased at. The value of the holding in EL.PA has fallen by EUR 63,602 (USD $74,834) compared to the previous valuation of EssilorLuxottica SA |
| ELV - Elevance Health Inc | HOLD | 0 @ USD 343.22 | USD 0 | The current share valuation price of ELV based on adjusted close was USD 343.22. The average price that ELV shares were previous bought at was USD 376.676. The current market price is -8.9% lower than average price they were purchased at. The value of the holding in ELV has fallen by USD 38,473 compared to the previous valuation of Elevance Health Inc |
| ELV - Elevance Health Inc | HOLD | 0 @ USD 343.22 | USD 0 | The current share valuation price of ELV based on adjusted close was USD 343.22. The average price that ELV shares were previous bought at was USD 376.676. The current market price is -8.9% lower than average price they were purchased at. The value of the holding in ELV has fallen by USD 38,473 compared to the previous valuation of Elevance Health Inc |
| ERF.PA - Eurofins Scientific SE | HOLD | 0 @ EUR 72.5575 | EUR 0 | The current share valuation price of ERF.PA based on adjusted close was EUR 72.5575. The average price that ERF.PA shares were previous bought at was EUR 55.9738. The current market price is 29.6% higher than average price they were purchased at. The value of the holding in ERF.PA has fallen by EUR 1,161 (USD $1,366) compared to the previous valuation of Eurofins Scientific SE |
| EW - Edwards Lifesciences Corp | HOLD | 0 @ USD 86.23 | USD 0 | The current share valuation price of EW based on adjusted close was USD 86.23. The average price that EW shares were previous bought at was USD 79.9952. The current market price is 7.8% higher than average price they were purchased at. The value of the holding in EW has fallen by USD 30,287 compared to the previous valuation of Edwards Lifesciences Corp |
| FME.DE - Fresenius Medical Care AG | HOLD | 0 @ EUR 47.936 | EUR 0 | The current share valuation price of FME.DE based on adjusted close was EUR 47.936. The average price that FME.DE shares were previous bought at was EUR 49.7628. The current market price is -3.7% lower than average price they were purchased at. The value of the holding in FME.DE has fallen by EUR 347 (USD $408) compared to the previous valuation of Fresenius Medical Care AG |
| FPH.NZ - | HOLD | 0 @ NZD 22.0355 | NZD 0 | The current share valuation price of FPH.NZ based on adjusted close was NZD 22.0355. The average price that FPH.NZ shares were previous bought at was NZD 21.3011. The current market price is 3.4% higher than average price they were purchased at. The value of the holding in FPH.NZ has increased by NZD 1,004 (USD $582) compared to the previous valuation of however if the holding was sold on 2025-12-23 this would crystalise an overall loss. |
| FRE.DE - Fresenius SE & Co KGaA | HOLD | 0 @ EUR 57.4149 | EUR 0 | The current share valuation price of FRE.DE based on adjusted close was EUR 57.4149. The average price that FRE.DE shares were previous bought at was EUR 53.2431. The current market price is 7.8% higher than average price they were purchased at. The value of the holding in FRE.DE has increased by EUR 3,005 (USD $3,536) compared to the previous valuation of Fresenius SE & Co KGaA however if the holding was sold on 2025-12-23 this would crystalise an overall loss. |
| GALD.SW - | HOLD | 0 @ CHF 207.761 | CHF 0 | The current share valuation price of GALD.SW based on adjusted close was CHF 207.761. The average price that GALD.SW shares were previous bought at was CHF 186.174. The current market price is 11.6% higher than average price they were purchased at. The value of the holding in GALD.SW has increased by CHF 5,041 (USD $6,369) compared to the previous valuation of however if the holding was sold on 2025-12-23 this would crystalise an overall loss. |
| GEHC - GE HealthCare Technologies Inc. | HOLD | 0 @ USD 83.32 | USD 0 | The current share valuation price of GEHC based on adjusted close was USD 83.32. The average price that GEHC shares were previous bought at was USD 79.0082. The current market price is 5.5% higher than average price they were purchased at. The value of the holding in GEHC has fallen by USD 6,358 compared to the previous valuation of GE HealthCare Technologies Inc. |
| GILD - Guild Esports Plc | HOLD | 0 @ USD 125.19 | USD 0 | The current share valuation price of GILD based on adjusted close was USD 125.19. The average price that GILD shares were previous bought at was USD 117.379. The current market price is 6.7% higher than average price they were purchased at. The value of the holding in GILD has increased by USD 158,647 compared to the previous valuation of Guild Esports Plc however if the holding was sold on 2025-12-23 this would crystalise an overall loss. |
| GMAB.CO - | HOLD | 0 @ DKK 334.676 | DKK 0 | The current share valuation price of GMAB.CO based on adjusted close was DKK 334.676. The average price that GMAB.CO shares were previous bought at was DKK 290.643. The current market price is 15.2% higher than average price they were purchased at. The value of the holding in GMAB.CO has increased by DKK 103,157 (USD $16,249) compared to the previous valuation of however if the holding was sold on 2025-12-23 this would crystalise an overall loss. |
| GRF.MC - Grifols SA | HOLD | 0 @ EUR 12.8465 | EUR 0 | The current share valuation price of GRF.MC based on adjusted close was EUR 12.8465. The average price that GRF.MC shares were previous bought at was EUR 12.9973. The current market price is -1.2% lower than average price they were purchased at. The value of the holding in GRF.MC has fallen by EUR 3,440 (USD $4,047) compared to the previous valuation of Grifols SA |
| GSK.L - GlaxoSmithKline PLC | HOLD | 0 @ GBP 24.4658 | GBP 0 | The current share valuation price of GSK.L based on adjusted close was GBP 24.4658. The average price that GSK.L shares were previous bought at was GBP 23.3868. The current market price is 4.6% higher than average price they were purchased at. The value of the holding in GSK.L has increased by GBP 25,220 (USD $33,971) compared to the previous valuation of GlaxoSmithKline PLC however if the holding was sold on 2025-12-23 this would crystalise an overall loss. |
| HCA - HCA Holdings Inc | HOLD | 0 @ USD 474.04 | USD 0 | The current share valuation price of HCA based on adjusted close was USD 474.04. The average price that HCA shares were previous bought at was USD 452.49. The current market price is 4.8% higher than average price they were purchased at. The value of the holding in HCA has increased by USD 8,400 compared to the previous valuation of HCA Holdings Inc however if the holding was sold on 2025-12-23 this would crystalise an overall loss. |
| HIK.L - | HOLD | 0 @ GBP 20.5758 | GBP 0 | The current share valuation price of HIK.L based on adjusted close was GBP 20.5758. The average price that HIK.L shares were previous bought at was GBP 22.5566. The current market price is -8.8% lower than average price they were purchased at. The value of the holding in HIK.L has increased by GBP 1,253 (USD $1,688) compared to the previous valuation of however if the holding was sold on 2025-12-23 this would crystalise an overall loss. |
| HLN.L - Haleon PLC | HOLD | 0 @ GBP 5.01721 | GBP 0 | The current share valuation price of HLN.L based on adjusted close was GBP 5.01721. The average price that HLN.L shares were previous bought at was GBP 4.88837. The current market price is 2.6% higher than average price they were purchased at. The value of the holding in HLN.L has increased by GBP 7,855 (USD $10,581) compared to the previous valuation of Haleon PLC however if the holding was sold on 2025-12-23 this would crystalise an overall loss. |
| HOLX - Hologic Inc | HOLD | 0 @ USD 74.87 | USD 0 | The current share valuation price of HOLX based on adjusted close was USD 74.87. The average price that HOLX shares were previous bought at was USD 71.3785. The current market price is 4.9% higher than average price they were purchased at. The value of the holding in HOLX has fallen by USD 3,290 compared to the previous valuation of Hologic Inc |
| HUM - Hummingbird Resources PLC | HOLD | 0 @ USD 257.12 | USD 0 | The current share valuation price of HUM based on adjusted close was USD 257.12. The average price that HUM shares were previous bought at was USD 300.713. The current market price is -14.5% lower than average price they were purchased at. The value of the holding in HUM has fallen by USD 10,340 compared to the previous valuation of Hummingbird Resources PLC |
| HUM - Humana Inc | HOLD | 0 @ USD 257.12 | USD 0 | The current share valuation price of HUM based on adjusted close was USD 257.12. The average price that HUM shares were previous bought at was USD 300.713. The current market price is -14.5% lower than average price they were purchased at. The value of the holding in HUM has fallen by USD 10,340 compared to the previous valuation of Humana Inc |
| IDXX - IDEXX Laboratories Inc | HOLD | 0 @ USD 682.31 | USD 0 | The current share valuation price of IDXX based on adjusted close was USD 682.31. The average price that IDXX shares were previous bought at was USD 633.134. The current market price is 7.8% higher than average price they were purchased at. The value of the holding in IDXX has fallen by USD 316,980 compared to the previous valuation of IDEXX Laboratories Inc |
| ILMN - Illumina Inc | HOLD | 0 @ USD 136.19 | USD 0 | The current share valuation price of ILMN based on adjusted close was USD 136.19. The average price that ILMN shares were previous bought at was USD 110.919. The current market price is 22.8% higher than average price they were purchased at. The value of the holding in ILMN has fallen by USD 4,804 compared to the previous valuation of Illumina Inc |
| INCY - Incyte Corporation | HOLD | 0 @ USD 100.91 | USD 0 | The current share valuation price of INCY based on adjusted close was USD 100.91. The average price that INCY shares were previous bought at was USD 104.454. The current market price is -3.4% lower than average price they were purchased at. The value of the holding in INCY has increased by USD 2,610 compared to the previous valuation of Incyte Corporation however if the holding was sold on 2025-12-23 this would crystalise an overall loss. |
| INSM - Insmed Inc | HOLD | 0 @ USD 176.77 | USD 0 | The current share valuation price of INSM based on adjusted close was USD 176.77. The average price that INSM shares were previous bought at was USD 200.537. The current market price is -11.9% lower than average price they were purchased at. The value of the holding in INSM has increased by USD 12,096 compared to the previous valuation of Insmed Inc however if the holding was sold on 2025-12-23 this would crystalise an overall loss. |
| IPN.PA - Ipsen SA | HOLD | 0 @ EUR 140.593 | EUR 0 | The current share valuation price of IPN.PA based on adjusted close was EUR 140.593. The average price that IPN.PA shares were previous bought at was EUR 136.967. The current market price is 2.6% higher than average price they were purchased at. The value of the holding in IPN.PA has increased by EUR 308 (USD $362) compared to the previous valuation of Ipsen SA however if the holding was sold on 2025-12-23 this would crystalise an overall loss. |
| IQV - IQVIA Holdings Inc | HOLD | 0 @ USD 225.15 | USD 0 | The current share valuation price of IQV based on adjusted close was USD 225.15. The average price that IQV shares were previous bought at was USD 203.879. The current market price is 10.4% higher than average price they were purchased at. The value of the holding in IQV has increased by USD 33,952 compared to the previous valuation of IQVIA Holdings Inc however if the holding was sold on 2025-12-23 this would crystalise an overall loss. |
| ISRG - Intuitive Surgical Inc | HOLD | 0 @ USD 577.34 | USD 0 | The current share valuation price of ISRG based on adjusted close was USD 577.34. The average price that ISRG shares were previous bought at was USD 540.112. The current market price is 6.9% higher than average price they were purchased at. The value of the holding in ISRG has fallen by USD 64,264 compared to the previous valuation of Intuitive Surgical Inc |
| JNJ - Johnson & Johnson | HOLD | 0 @ USD 205.78 | USD 0 | The current share valuation price of JNJ based on adjusted close was USD 205.78. The average price that JNJ shares were previous bought at was USD 172.462. The current market price is 19.3% higher than average price they were purchased at. The value of the holding in JNJ has fallen by USD 246,537 compared to the previous valuation of Johnson & Johnson |
| LH - Laboratory Corporation of America Holdings | HOLD | 0 @ USD 253.15 | USD 0 | The current share valuation price of LH based on adjusted close was USD 253.15. The average price that LH shares were previous bought at was USD 262.999. The current market price is -3.7% lower than average price they were purchased at. The value of the holding in LH has fallen by USD 3,512 compared to the previous valuation of Laboratory Corporation of America Holdings |
| LLY - Eli Lilly and Company | HOLD | 0 @ USD 1071.64 | USD 0 | The current share valuation price of LLY based on adjusted close was USD 1071.64. The average price that LLY shares were previous bought at was USD 868.916. The current market price is 23.3% higher than average price they were purchased at. The value of the holding in LLY has fallen by USD 336,966 compared to the previous valuation of Eli Lilly and Company |
| LONN.SW - | HOLD | 0 @ CHF 674.812 | CHF 0 | The current share valuation price of LONN.SW based on adjusted close was CHF 674.812. The average price that LONN.SW shares were previous bought at was CHF 671.524. The current market price is 0.5% higher than average price they were purchased at. The value of the holding in LONN.SW has increased by CHF 6,210 (USD $7,847) compared to the previous valuation of however if the holding was sold on 2025-12-23 this would crystalise an overall loss. |
| MCK - McKesson Corporation | HOLD | 0 @ USD 825.73 | USD 0 | The current share valuation price of MCK based on adjusted close was USD 825.73. The average price that MCK shares were previous bought at was USD 787.313. The current market price is 4.9% higher than average price they were purchased at. The value of the holding in MCK has increased by USD 120,813 compared to the previous valuation of McKesson Corporation however if the holding was sold on 2025-12-23 this would crystalise an overall loss. |
| MDT - Medtronic PLC | HOLD | 0 @ USD 97.47 | USD 0 | The current share valuation price of MDT based on adjusted close was USD 97.47. The average price that MDT shares were previous bought at was USD 97.8271. The current market price is -0.4% lower than average price they were purchased at. The value of the holding in MDT has fallen by USD 8,626 compared to the previous valuation of Medtronic PLC |
| MRK - Marks Electrical Group PLC | HOLD | 0 @ USD 105.04 | USD 0 | The current share valuation price of MRK based on adjusted close was USD 105.04. The average price that MRK shares were previous bought at was USD 91.3356. The current market price is 15.0% higher than average price they were purchased at. The value of the holding in MRK has increased by USD 59,031 compared to the previous valuation of Marks Electrical Group PLC however if the holding was sold on 2025-12-23 this would crystalise an overall loss. |
| MRK - Merck & Company Inc | HOLD | 0 @ USD 105.04 | USD 0 | The current share valuation price of MRK based on adjusted close was USD 105.04. The average price that MRK shares were previous bought at was USD 91.3356. The current market price is 15.0% higher than average price they were purchased at. The value of the holding in MRK has increased by USD 59,031 compared to the previous valuation of Merck & Company Inc however if the holding was sold on 2025-12-23 this would crystalise an overall loss. |
| MRK.DE - Merck KGaA | HOLD | 0 @ EUR 141.948 | EUR 0 | The current share valuation price of MRK.DE based on adjusted close was EUR 141.948. The average price that MRK.DE shares were previous bought at was EUR 133.142. The current market price is 6.6% higher than average price they were purchased at. The value of the holding in MRK.DE has increased by EUR 1,880 (USD $2,212) compared to the previous valuation of Merck KGaA however if the holding was sold on 2025-12-23 this would crystalise an overall loss. |
| MTD - Mettler-Toledo International Inc | HOLD | 0 @ USD 1414.6 | USD 0 | The current share valuation price of MTD based on adjusted close was USD 1414.6. The average price that MTD shares were previous bought at was USD 1459.84. The current market price is -3.1% lower than average price they were purchased at. The value of the holding in MTD has increased by USD 5,392 compared to the previous valuation of Mettler-Toledo International Inc however if the holding was sold on 2025-12-23 this would crystalise an overall loss. |
| MTD - AMUNDI EUR GOV 710 | HOLD | 0 @ USD 1414.6 | USD 0 | The current share valuation price of MTD based on adjusted close was USD 1414.6. The average price that MTD shares were previous bought at was USD 1459.84. The current market price is -3.1% lower than average price they were purchased at. The value of the holding in MTD has increased by USD 5,392 compared to the previous valuation of AMUNDI EUR GOV 710 however if the holding was sold on 2025-12-23 this would crystalise an overall loss. |
| NBIX - Neurocrine Biosciences Inc | HOLD | 0 @ USD 147.28 | USD 0 | The current share valuation price of NBIX based on adjusted close was USD 147.28. The average price that NBIX shares were previous bought at was USD 143.546. The current market price is 2.6% higher than average price they were purchased at. The value of the holding in NBIX has fallen by USD 505 compared to the previous valuation of Neurocrine Biosciences Inc |
| NOVN.SW - | HOLD | 0 @ CHF 139.394 | CHF 0 | The current share valuation price of NOVN.SW based on adjusted close was CHF 139.394. The average price that NOVN.SW shares were previous bought at was CHF 125.253. The current market price is 11.3% higher than average price they were purchased at. The value of the holding in NOVN.SW has increased by CHF 568,937 (USD $718,872) compared to the previous valuation of however if the holding was sold on 2025-12-23 this would crystalise an overall loss. |
| NOVO-B.CO - Novo Nordisk A/S | HOLD | 0 @ DKK 52.2665 | DKK 0 | The current share valuation price of NOVO-B.CO based on adjusted close was DKK 52.2665. The average price that NOVO-B.CO shares were previous bought at was DKK 54.008. The current market price is -3.2% lower than average price they were purchased at. The value of the holding in NOVO-B.CO has increased by DKK 1,402,450 (USD $220,908) compared to the previous valuation of Novo Nordisk A/S however if the holding was sold on 2025-12-23 this would crystalise an overall loss. |
| NTRA - Natera Inc | HOLD | 0 @ USD 235.4 | USD 0 | The current share valuation price of NTRA based on adjusted close was USD 235.4. The average price that NTRA shares were previous bought at was USD 183.463. The current market price is 28.3% higher than average price they were purchased at. The value of the holding in NTRA has fallen by USD 565 compared to the previous valuation of Natera Inc |
| ORNBV.HE - Orion Oyj | HOLD | 0 @ EUR 74.8301 | EUR 0 | The current share valuation price of ORNBV.HE based on adjusted close was EUR 74.8301. The average price that ORNBV.HE shares were previous bought at was EUR 68.1688. The current market price is 9.8% higher than average price they were purchased at. The value of the holding in ORNBV.HE has increased by EUR 2,970 (USD $3,494) compared to the previous valuation of Orion Oyj however if the holding was sold on 2025-12-23 this would crystalise an overall loss. |
| PFE - Pfizer Inc | HOLD | 0 @ USD 24.88 | USD 0 | The current share valuation price of PFE based on adjusted close was USD 24.88. The average price that PFE shares were previous bought at was USD 24.8577. The current market price is 0.1% higher than average price they were purchased at. The value of the holding in PFE has fallen by USD 89,001 compared to the previous valuation of Pfizer Inc |
| PHIA.AS - Koninklijke Philips NV | HOLD | 0 @ EUR 26.8352 | EUR 0 | The current share valuation price of PHIA.AS based on adjusted close was EUR 26.8352. The average price that PHIA.AS shares were previous bought at was EUR 26.6827. The current market price is 0.6% higher than average price they were purchased at. The value of the holding in PHIA.AS has fallen by EUR 2,060 (USD $2,424) compared to the previous valuation of Koninklijke Philips NV |
| PME.AX - | HOLD | 0 @ AUD 155.357 | AUD 0 | The current share valuation price of PME.AX based on adjusted close was AUD 155.357. The average price that PME.AX shares were previous bought at was AUD 173.012. The current market price is -10.2% lower than average price they were purchased at. The value of the holding in PME.AX has increased by AUD 11,868 (USD $7,902) compared to the previous valuation of however if the holding was sold on 2025-12-23 this would crystalise an overall loss. |
| PODD - Insulet Corporation | HOLD | 0 @ USD 285.5 | USD 0 | The current share valuation price of PODD based on adjusted close was USD 285.5. The average price that PODD shares were previous bought at was USD 330.02. The current market price is -13.5% lower than average price they were purchased at. The value of the holding in PODD has fallen by USD 19,308 compared to the previous valuation of Insulet Corporation |
| REC.MI - Recordati Industria Chimica e Farmaceutica SpA | HOLD | 0 @ EUR 57.3208 | EUR 0 | The current share valuation price of REC.MI based on adjusted close was EUR 57.3208. The average price that REC.MI shares were previous bought at was EUR 58.1381. The current market price is -1.4% lower than average price they were purchased at. The value of the holding in REC.MI has increased by EUR 1,863 (USD $2,192) compared to the previous valuation of Recordati Industria Chimica e Farmaceutica SpA however if the holding was sold on 2025-12-23 this would crystalise an overall loss. |
| REGN - Regeneron Pharmaceuticals Inc | HOLD | 0 @ USD 785.17 | USD 0 | The current share valuation price of REGN based on adjusted close was USD 785.17. The average price that REGN shares were previous bought at was USD 716.096. The current market price is 9.6% higher than average price they were purchased at. The value of the holding in REGN has increased by USD 41,832 compared to the previous valuation of Regeneron Pharmaceuticals Inc however if the holding was sold on 2025-12-23 this would crystalise an overall loss. |
| RMD - ResMed Inc | HOLD | 0 @ USD 244.6 | USD 0 | The current share valuation price of RMD based on adjusted close was USD 244.6. The average price that RMD shares were previous bought at was USD 255.171. The current market price is -4.1% lower than average price they were purchased at. The value of the holding in RMD has fallen by USD 9,052 compared to the previous valuation of ResMed Inc |
| RO.SW - | HOLD | 0 @ CHF 426.917 | CHF 0 | The current share valuation price of RO.SW based on adjusted close was CHF 426.917. The average price that RO.SW shares were previous bought at was CHF 347.116. The current market price is 23.0% higher than average price they were purchased at. The value of the holding in RO.SW has increased by CHF 47,160 (USD $59,588) compared to the previous valuation of however if the holding was sold on 2025-12-23 this would crystalise an overall loss. |
| ROG.SW - | HOLD | 0 @ CHF 417.294 | CHF 0 | The current share valuation price of ROG.SW based on adjusted close was CHF 417.294. The average price that ROG.SW shares were previous bought at was CHF 363.075. The current market price is 14.9% higher than average price they were purchased at. The value of the holding in ROG.SW has increased by CHF 336,267 (USD $424,885) compared to the previous valuation of however if the holding was sold on 2025-12-23 this would crystalise an overall loss. |
| RPRX - Royalty Pharma Plc | HOLD | 0 @ USD 39.39 | USD 0 | The current share valuation price of RPRX based on adjusted close was USD 39.39. The average price that RPRX shares were previous bought at was USD 37.3706. The current market price is 5.4% higher than average price they were purchased at. The value of the holding in RPRX has increased by USD 4,727 compared to the previous valuation of Royalty Pharma Plc however if the holding was sold on 2025-12-23 this would crystalise an overall loss. |
| SAN.PA - Sanofi SA | HOLD | 0 @ EUR 96.814 | EUR 0 | The current share valuation price of SAN.PA based on adjusted close was EUR 96.814. The average price that SAN.PA shares were previous bought at was EUR 98.7892. The current market price is -2.0% lower than average price they were purchased at. The value of the holding in SAN.PA has increased by EUR 49,066 (USD $57,731) compared to the previous valuation of Sanofi SA however if the holding was sold on 2025-12-23 this would crystalise an overall loss. |
| SDZ.SW - | HOLD | 0 @ CHF 74.2166 | CHF 0 | The current share valuation price of SDZ.SW based on adjusted close was CHF 74.2166. The average price that SDZ.SW shares were previous bought at was CHF 60.542. The current market price is 22.6% higher than average price they were purchased at. The value of the holding in SDZ.SW has increased by CHF 5,803 (USD $7,332) compared to the previous valuation of however if the holding was sold on 2025-12-23 this would crystalise an overall loss. |
| SHL.AX - | HOLD | 0 @ AUD 15.2566 | AUD 0 | The current share valuation price of SHL.AX based on adjusted close was AUD 15.2566. The average price that SHL.AX shares were previous bought at was AUD 15.0557. The current market price is 1.3% higher than average price they were purchased at. The value of the holding in SHL.AX has increased by AUD 5,417 (USD $3,607) compared to the previous valuation of however if the holding was sold on 2025-12-23 this would crystalise an overall loss. |
| SHL.DE - Siemens Healthineers AG | HOLD | 0 @ EUR 52.3988 | EUR 0 | The current share valuation price of SHL.DE based on adjusted close was EUR 52.3988. The average price that SHL.DE shares were previous bought at was EUR 53.1296. The current market price is -1.4% lower than average price they were purchased at. The value of the holding in SHL.DE has fallen by EUR 1,761 (USD $2,072) compared to the previous valuation of Siemens Healthineers AG |
| SIG.AX - | HOLD | 0 @ AUD 1.98738 | AUD 0 | The current share valuation price of SIG.AX based on adjusted close was AUD 1.98738. The average price that SIG.AX shares were previous bought at was AUD 1.89951. The current market price is 4.6% higher than average price they were purchased at. The value of the holding in SIG.AX has increased by AUD 16,507 (USD $10,991) compared to the previous valuation of however if the holding was sold on 2025-12-23 this would crystalise an overall loss. |
| SN.L - Smith & Nephew PLC | HOLD | 0 @ GBP 16.4499 | GBP 0 | The current share valuation price of SN.L based on adjusted close was GBP 16.4499. The average price that SN.L shares were previous bought at was GBP 17.1365. The current market price is -4.0% lower than average price they were purchased at. The value of the holding in SN.L has fallen by GBP 1,596 (USD $2,150) compared to the previous valuation of Smith & Nephew PLC |
| SOBI.ST - | HOLD | 0 @ SEK 35.8718 | SEK 0 | The current share valuation price of SOBI.ST based on adjusted close was SEK 35.8718. The average price that SOBI.ST shares were previous bought at was SEK 33.2171. The current market price is 8.0% higher than average price they were purchased at. The value of the holding in SOBI.ST has fallen by SEK 372 (USD $40) compared to the previous valuation of |
| SOLV - Solventum Corp. | HOLD | 0 @ USD 80.5499 | USD 0 | The current share valuation price of SOLV based on adjusted close was USD 80.5499. The average price that SOLV shares were previous bought at was USD 74.8162. The current market price is 7.7% higher than average price they were purchased at. The value of the holding in SOLV has fallen by USD 956 compared to the previous valuation of Solventum Corp. |
| SOON.SW - | HOLD | 0 @ CHF 260.556 | CHF 0 | The current share valuation price of SOON.SW based on adjusted close was CHF 260.556. The average price that SOON.SW shares were previous bought at was CHF 269.657. The current market price is -3.4% lower than average price they were purchased at. The value of the holding in SOON.SW has fallen by CHF 17,671 (USD $22,328) compared to the previous valuation of |
| SRT3.DE - Sartorius AG | HOLD | 0 @ EUR 289.076 | EUR 0 | The current share valuation price of SRT3.DE based on adjusted close was EUR 289.076. The average price that SRT3.DE shares were previous bought at was EUR 261.575. The current market price is 10.5% higher than average price they were purchased at. The value of the holding in SRT3.DE has increased by EUR 11,976 (USD $14,091) compared to the previous valuation of Sartorius AG however if the holding was sold on 2025-12-23 this would crystalise an overall loss. |
| STE - STERIS plc | HOLD | 0 @ USD 255.39 | USD 0 | The current share valuation price of STE based on adjusted close was USD 255.39. The average price that STE shares were previous bought at was USD 230.644. The current market price is 10.7% higher than average price they were purchased at. The value of the holding in STE has increased by USD 9,087 compared to the previous valuation of STERIS plc however if the holding was sold on 2025-12-23 this would crystalise an overall loss. |
| STMN.SW - | HOLD | 0 @ CHF 117.567 | CHF 0 | The current share valuation price of STMN.SW based on adjusted close was CHF 117.567. The average price that STMN.SW shares were previous bought at was CHF 121.264. The current market price is -3.0% lower than average price they were purchased at. The value of the holding in STMN.SW has fallen by CHF 5,959 (USD $7,529) compared to the previous valuation of |
| SYK - Stryker Corporation | HOLD | 0 @ USD 354.82 | USD 0 | The current share valuation price of SYK based on adjusted close was USD 354.82. The average price that SYK shares were previous bought at was USD 368.773. The current market price is -3.8% lower than average price they were purchased at. The value of the holding in SYK has fallen by USD 28,514 compared to the previous valuation of Stryker Corporation |
| TEVA - Teva Pharma Industries Ltd ADR | HOLD | 0 @ USD 31.54 | USD 0 | The current share valuation price of TEVA based on adjusted close was USD 31.54. The average price that TEVA shares were previous bought at was USD 21.0113. The current market price is 50.1% higher than average price they were purchased at. The value of the holding in TEVA has increased by USD 8,251 compared to the previous valuation of Teva Pharma Industries Ltd ADR however if the holding was sold on 2025-12-23 this would crystalise an overall loss. |
| TMO - Time Out Group plc | HOLD | 0 @ USD 579.94 | USD 0 | The current share valuation price of TMO based on adjusted close was USD 579.94. The average price that TMO shares were previous bought at was USD 486.491. The current market price is 19.2% higher than average price they were purchased at. The value of the holding in TMO has increased by USD 97,334 compared to the previous valuation of Time Out Group plc however if the holding was sold on 2025-12-23 this would crystalise an overall loss. |
| UCB.BR - UCB SA | HOLD | 0 @ EUR 283.542 | EUR 0 | The current share valuation price of UCB.BR based on adjusted close was EUR 283.542. The average price that UCB.BR shares were previous bought at was EUR 214.091. The current market price is 32.4% higher than average price they were purchased at. The value of the holding in UCB.BR has increased by EUR 94,805 (USD $111,547) compared to the previous valuation of UCB SA however if the holding was sold on 2025-12-23 this would crystalise an overall loss. |
| UNH - UnitedHealth Group Incorporated | HOLD | 0 @ USD 324.8 | USD 0 | The current share valuation price of UNH based on adjusted close was USD 324.8. The average price that UNH shares were previous bought at was USD 419.15. The current market price is -22.5% lower than average price they were purchased at. The value of the holding in UNH has fallen by USD 26,152 compared to the previous valuation of UnitedHealth Group Incorporated |
| UTHR - United Therapeutics Corporation | HOLD | 0 @ USD 510.44 | USD 0 | The current share valuation price of UTHR based on adjusted close was USD 510.44. The average price that UTHR shares were previous bought at was USD 444.475. The current market price is 14.8% higher than average price they were purchased at. The value of the holding in UTHR has fallen by USD 3,266 compared to the previous valuation of United Therapeutics Corporation |
| VEEV - Veeva Systems Inc Class A | HOLD | 0 @ USD 224.26 | USD 0 | The current share valuation price of VEEV based on adjusted close was USD 224.26. The average price that VEEV shares were previous bought at was USD 270.08. The current market price is -17.0% lower than average price they were purchased at. The value of the holding in VEEV has increased by USD 26,450 compared to the previous valuation of Veeva Systems Inc Class A however if the holding was sold on 2025-12-23 this would crystalise an overall loss. |
| VRTX - Vertex Pharmaceuticals Inc | HOLD | 0 @ USD 459.21 | USD 0 | The current share valuation price of VRTX based on adjusted close was USD 459.21. The average price that VRTX shares were previous bought at was USD 428.315. The current market price is 7.2% higher than average price they were purchased at. The value of the holding in VRTX has fallen by USD 36,180 compared to the previous valuation of Vertex Pharmaceuticals Inc |
| WAT - Waters Corporation | HOLD | 0 @ USD 383.21 | USD 0 | The current share valuation price of WAT based on adjusted close was USD 383.21. The average price that WAT shares were previous bought at was USD 350.665. The current market price is 9.3% higher than average price they were purchased at. The value of the holding in WAT has fallen by USD 15,560 compared to the previous valuation of Waters Corporation |
| WAT - MULETFWATIMETFP | HOLD | 0 @ USD 383.21 | USD 0 | The current share valuation price of WAT based on adjusted close was USD 383.21. The average price that WAT shares were previous bought at was USD 350.665. The current market price is 9.3% higher than average price they were purchased at. The value of the holding in WAT has fallen by USD 15,560 compared to the previous valuation of MULETFWATIMETFP |
| WST - West Pharmaceutical Services Inc | HOLD | 0 @ USD 277.49 | USD 0 | The current share valuation price of WST based on adjusted close was USD 277.49. The average price that WST shares were previous bought at was USD 268.173. The current market price is 3.5% higher than average price they were purchased at. The value of the holding in WST has increased by USD 4,240 compared to the previous valuation of West Pharmaceutical Services Inc however if the holding was sold on 2025-12-23 this would crystalise an overall loss. |
| ZBH - Zimmer Biomet Holdings Inc | HOLD | 0 @ USD 89.43 | USD 0 | The current share valuation price of ZBH based on adjusted close was USD 89.43. The average price that ZBH shares were previous bought at was USD 96.1848. The current market price is -7.0% lower than average price they were purchased at. The value of the holding in ZBH has fallen by USD 1,694 compared to the previous valuation of Zimmer Biomet Holdings Inc |
| ZTS - Zoetis Inc | HOLD | 0 @ USD 123.54 | USD 0 | The current share valuation price of ZTS based on adjusted close was USD 123.54. The average price that ZTS shares were previous bought at was USD 135.038. The current market price is -8.5% lower than average price they were purchased at. The value of the holding in ZTS has fallen by USD 22,119 compared to the previous valuation of Zoetis Inc |